Atlas Trials

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Clinical trial NCT02282059 · COMPLETED

Trial details

NCT number
NCT02282059
Sponsor
Pfizer
Status
COMPLETED
Study type
OBSERVATIONAL
Pancreatic Neuroendocrine Tumors
Start date
2014-12-12
Primary completion
2022-12-12
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.